Navigation Links
Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009
Date:11/16/2009

BEDFORD, Mass., Nov. 16 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, is participating in the 38(th) Annual American Association of Gynecologic Laparoscopists (AAGL) conference, November 15-19, 2009 in Orlando, Florida, and will feature its Adiana(®) permanent contraception system.

Adiana is a minimally invasive procedure that requires no incisions and can be performed in the comfort of the doctor's office using local anesthesia. The Adiana system is designed to provide women a minimally invasive alternative to traditional, surgical means of permanent contraception. With the Adiana system, patients are normally able to return to work or resume their daily activities within one day. In contrast, traditional methods of permanent contraception, such as tubal ligation, require more invasive surgical procedures, usually are conducted in a hospital under general anesthesia, and typically require four to five days of recovery.

"AAGL is the most influential meeting for physicians providing patient care through minimally invasive gynecology," said Tony Kingsley, senior vice president, GYN surgical products at Hologic. "As we have learned through numerous patient testimonials, women are undergoing the Adiana procedure to seek relief from the uncertainty and hassle of temporary birth control methods. At Hologic, we continue to bring to market tools that allow physicians to offer women in-office alternatives for their long-term contraception and other gynecological needs."

At AAGL, physicians will present open communication sessions and poster presentations on the Adiana system and the hysteroscopic sterilization method used during the Adiana procedure. Primary investigators will present new data from studies on the Adiana system.

Approved by the Food and Drug Administration (FDA) in July 2009, the Adiana procedure is indicated for women who desire permanent birth control by occlusion of the fallopian tubes.

Ideal candidates include women who do not want children in the future and would like the peace of mind and convenience of permanent birth control.

Sessions for information and key findings about Adiana at AAGL include:

  • "Adiana System for Transcervical Sterilization: 3-Year Efficacy Results;" presented by T.L. Anderson, T.G. Vancaillie; Open Communications; 6 -- Hysteroscopy (Wednesday, 11/18 at 11:48 pm)
  • "Mechanism of Action of the Adiana Device: A Histologic Perspective;" presented by T.G. Vancaillie, D. Harrington, V. Carr-Brendel, J. Anderson; Open Communications; 14 -- Hysteroscopy (Wednesday, 11/18 at 3:44 pm)
  • "Evaluating the Learning Curve for a Novel Hysteroscopic Sterilization Technique;" presented by M.Y. Bongers, S. Veersema; Open Communications; 16 -- Hysteroscopy (Thursday, 11/19 at 8:12 am)
  • "Feasibility of Hysterosalpingography To Evaluate Tubal Occlusion Following Concomitant Adiana(®) Transcervical Sterilization and NovaSure(®) Endometrial Ablation;" presented by J. Garza-Leal, I. Hernandez, L. Castillo, R. Livengood, M. Stillman, J.E. Coad; Poster Presentation
  • "Concominant Use of Adiana(®) Permanent Contraception and NovaSure(®) Impedance Controlled Endometrial Ablation: A Peri-Hysterectomy Study;" presented by J. Garza-Leal, I. Hernandez, L. Castillo, R. Livengood, M. Stillman, J.E. Coad; Open Communications; 14 -- Hysteroscopy (Wednesday, 11/18 at 3:26 pm)

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Forward-Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the Adiana permanent contraception system. There can be no assurance the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the Adiana permanent contraception system can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.

Hologic, Adiana and NovaSure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

    Contact:  Stephanie Cilibrasi                          Anne Rivers
              Product Manager, Adiana Product Marketing    Corporate Marketing
              Hologic, Inc.                                Hologic, Inc.
              (339) 221-3292                               (508) 263-8765
              Email: adianamedia@hologic.com

SOURCE Hologic, Inc.


'/>"/>
SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... specifically to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers ... alternative to dairy proteins, providing direct cost savings as well as more stable ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... and collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 ... experience for education and business. , Mirroring360 Pro enables educators, business professionals and ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... a modern procedure that achieves results in a fraction of the time as ... Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with or ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
Breaking Medicine News(10 mins):